Newsroom Voices Saniona’s CEO on progress in 2020 and the way forward May 6, 2021 | Source BioStock Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome March 4, 2021 | Source BioStock Why I Prioritized Patient Advocacy When Building Saniona February 8, 2021 | Source LinkedIn Saniona’s CCO on the Importance of Communication February 4, 2021 | Source BioStock Saniona's CEO on the plans for 2021 January 12, 2021 | Source BioStock Saniona’s chairman aims to recruit America’s best talents October 20, 2020 | Source BioStock Studio
Saniona’s CEO on progress in 2020 and the way forward May 6, 2021 | Source BioStock Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome March 4, 2021 | Source BioStock Why I Prioritized Patient Advocacy When Building Saniona February 8, 2021 | Source LinkedIn Saniona’s CCO on the Importance of Communication February 4, 2021 | Source BioStock Saniona's CEO on the plans for 2021 January 12, 2021 | Source BioStock Saniona’s chairman aims to recruit America’s best talents October 20, 2020 | Source BioStock Studio
Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome March 4, 2021 | Source BioStock
